Tiger Brokers

英硅智能盘中涨超8%破顶 NLRP3抑制剂ISM8969获FDA临床试验批件

金融界
Jan 23

英硅智能（03696）盘中涨超8%，高见64.40港元，创上市新高。截至发稿，股价上涨6.37%，现报62.65港元，成交额5074.78万港元。

英硅智能今日宣布，其用于炎症及神经退行性疾病治疗的口服NLRP3抑制剂ISM8969临床试验新药（IND）申请获得美国食品药品监督管理局（FDA）批准，用于帕金森病治疗。即将开展的这项I期临床研究旨在评估ISM8969在健康人群中的安全性、耐受性及药代动力学表现，并找到临床推荐最佳剂量以供后续的进一步研究。值得一提的是，为加速ISM8969的全球开发，英硅智能已与衡泰生物达成共同开发合作协议。双方各持有该项目50%的全球权益，同时英硅智能有权获得最高逾5亿港币的预付款和里程碑付款。

此外，英硅智能日前发布了大语言模型训练框架Science MMAI Gym，旨在将具有因果推理能力的LLM转化为具备在真实世界处理药物发现与开发任务能力的高性能引擎。 经过训练后，原本在专业任务领域失败率高达75%–95%的 LLM，可在关键药物发现基准测试中实现最高 10 倍的性能提升。此次发布将进一步推进制药超级智能（PSI）愿景。

港股频道更多独家策划、专家专栏，免费查阅>>

责任编辑：栎树

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10